Journal article
Low-Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)
Thompson G Robinson, Xia Wang, Hisatomi Arima, Philip M Bath, Laurent Billot, Joseph P Broderick, Andrew M Demchuk, Geoffery A Donnan, Jong S Kim, Pablo M Lavados, Tsong-Hai Lee, Richard I Lindley, Sheila CO Martins, Veronica V Olavarria, Jeyaraj D Pandian, Mark W Parsons, Octavio M Pontes-Neto, Stefano Ricci, Shoichiro Sato, Vijay K Sharma Show all
STROKE | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Abstract
BACKGROUND AND PURPOSE: Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study). METHODS: Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior AP..
View full abstractGrants
Awarded by Ministry of Health of Brazil
Awarded by National Council for Scientific and Technological Development of Brazil
Awarded by Ministry for Health, Welfare, and Family Affairs of the Republic of Korea
Awarded by National Institute for Health Research
Awarded by Alberta Innovates
Awarded by Stroke Association
Funding Acknowledgements
The study is supported by grants from the National Health and Medical Research Council of Australia, the Stroke Association of the United Kingdom, the Ministry of Health and the National Council for Scientific and Technological Development of Brazil (467322/2014-7 and 402388/2013-5), and the Ministry for Health, Welfare, and Family Affairs of the Republic of Korea (HI14C1985).